RenovoRx, Inc.

RenovoRx reported a significant increase in Q2 2026 revenue, rising 115.4% to $909,000, with gross profit up 183.7% to $766,000. Despite this, the company posted a net loss of $(2.91) million for the quarter and $(6.43) million for the first six months of 2026. RenovoRx also received an additional Orphan Drug Designation for oxaliplatin for pancreatic cancer and initiated a new investigator-initiated trial for cholangiocarcinoma. The company believes its current cash and cash equivalents of $9.5 million are sufficient to fund operations for at least the next 12 months.

RenovoRx, Inc. reported record second-quarter 2026 financial results, with revenue reaching $909,000, a 115% increase year-over-year and 61% sequentially. The company raised its full-year 2026 revenue guidance to a range of $3.75 million to $4.25 million. Operational highlights include the expansion of RenovoCath use to sarcoma patients, full enrollment in the Phase III TIGeR-PaC trial, and an increase to 21 active commercial cancer center customers.

RenovoRx, Inc. announced the completion of enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer (LAPC) as of August 7, 2026. The trial, which evaluates intra-arterial gemcitabine (IAG) via RenovoCath, is expected to be completed in the first half of 2027, with initial top-line data anticipated in the second half of 2027. This milestone reflects successful patient recruitment and clinical execution for a therapy targeting a significant unmet medical need.

RenovoRx announced the first commercial clinical use of its FDA-cleared RenovoCath device for drug delivery in the treatment of a sarcoma patient at CARTI Cancer Center. This marks an important milestone, demonstrating the device's potential for other solid tumors beyond its core focus on pancreatic cancer. The company also reported approximately $1.1 million in RenovoCath sales for 2025 and $563,000 in Q1 2026, while anticipating full enrollment in its Phase III TIGeR-PaC trial soon.

RenovoRx, Inc. announced its participation in a JonesTrading webinar on August 13, 2026, to discuss its Trans-Arterial Micro-Perfusion (TAMP) platform and emerging clinical advances in pancreatic cancer. The webinar will cover the ongoing Phase III TIGeR-PaC clinical trial and the commercial progress of RenovoCath. The company reported RenovoCath sales of approximately $1.1 million in 2025 and a record $563,000 in Q1 2026, with full enrollment for TIGeR-PaC expected soon and data readout in mid to late 2027.

RenovoRx, Inc. announced it will host its second quarter 2026 financial results and business highlights conference call on August 12, 2026, at 4:30 p.m. ET. Management plans to discuss growing revenues from RenovoCath sales, increased adoption at U.S. cancer centers, and an update on the Phase III TIGeR-PaC clinical trial, which expects full enrollment soon and final data in mid-to-late 2027. The company also highlighted recent FDA Orphan Drug Designation for oxaliplatin in pancreatic cancer and continued expansion of its TAMP therapy platform.

RenovoRx, Inc. received a notification from Nasdaq granting an additional 180-day period to regain compliance with the $1.00 minimum bid price requirement. The new deadline for compliance is December 28, 2026. The company had previously received a deficiency notice on December 31, 2025, with an initial compliance period ending on June 30, 2026. If compliance is not met by the new deadline, the common stock may be delisted from Nasdaq.

RenovoRx, Inc. held its 2026 annual meeting of stockholders on June 30, 2026. During the meeting, stockholders elected six directors to serve for a one-year term. Additionally, an amendment to the 2021 Omnibus Equity Incentive Plan was approved, adding 2,000,000 shares of common stock, representing 4.4% of total outstanding shares, to the plan. Stockholders also ratified the appointment of Frank, Rimerman + Co. LLP as the company's independent registered public accounting firm for the year ending December 31, 2026.

RenovoRx, Inc. announced that CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23, 2026. He will discuss the company's record first quarter 2026 revenue of $563,000, driven by growing demand for RenovoCath, and the expected completion of enrollment in its Phase III TIGeR-PaC clinical trial by the end of June 2026. Mr. Bagai will also provide updates on the trial's progress and the recent FDA Orphan Drug Designation for oxaliplatin for pancreatic cancer, which is the company's third overall ODD.

RenovoRx, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for oxaliplatin for the treatment of pancreatic cancer. This is the company's second ODD in pancreatic cancer and third overall, underscoring its targeted intra-arterial drug-delivery approach using the RenovoCath device. The ODD provides significant regulatory and financial benefits, including seven years of market exclusivity upon FDA approval, a 25% federal tax credit on clinical research expenses, and a waiver of FDA application fees. RenovoRx continues to advance its therapeutic pipeline, including the Phase III TIGeR-PaC trial, and expand commercialization of RenovoCath.